Yuk-Ying Chan
Overview
Explore the profile of Yuk-Ying Chan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
352
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin P, Hung M, Shao S, Chen H, Chan Y, Chang K, et al.
Cancer Med
. 2023 Jun;
12(14):14902-14911.
PMID: 37278402
Purpose: The aim of this study was to investigate the factors predictive of clinical outcome in advanced hepatocellular carcinoma patients receiving ramucirumab treatment. Methods: We conducted a retrospective study using...
2.
Chang K, Shao S, Chen H, Chan Y, Fang Y
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267465
Fixed doses at 200 mg of pembrolizumab or 2 mg/kg every 3 weeks are the standard dosages for first- and second-line treatment of non-small-cell lung cancer (NSCLC); however, in clinical...
3.
Shao S, Chang K, Lin S, Chang S, Hung M, Chan Y, et al.
Cardiovasc Diabetol
. 2021 Oct;
20(1):213.
PMID: 34688282
Background: The treatment effects on hospitalization for heart failure (hHF) from sodium-glucose cotransporter 2 (SGLT2) inhibitors may vary among type 2 diabetes (T2D) patients depending on whether or not they...
4.
Chen H, Shao S, Weng M, Lin S, Hung M, Chan Y, et al.
Clin Pharmacol Ther
. 2021 Sep;
110(6):1595-1603.
PMID: 34496051
This is a retrospective cohort study by analyzing a multi-institutional electronic medical records database covering 1.3 million individuals (6% of Taiwan's population) to compare the risk of heart failure (HF)...
5.
Shao S, Lai E, Huang T, Hung M, Tsai M, Yang Y, et al.
Pharmacoepidemiol Drug Saf
. 2021 Feb;
30(5):652-660.
PMID: 33611792
Background: The Chang Gung Research Database (CGRD), the largest multi-institutional electronic medical records collection in Taiwan, has been used to establish real-world evidence related to traditional Chinese medicine (TCM). We...
6.
Shao S, Lai E, Chen Y, Chan Y, Chen H
J Patient Saf
. 2020 Oct;
17(1):e43-e44.
PMID: 33074933
No abstract available.
7.
Chang K, Shao S, Kuo S, Yang C, Chen H, Chan Y, et al.
Cardiovasc Diabetol
. 2020 Oct;
19(1):172.
PMID: 33036617
Background: Head-to-head comparison of clinical effectiveness between dulaglutide and liraglutide in Asia is limited. This study was aimed to assess the real-world comparative effectiveness of dulaglutide versus liraglutide. Methods: We...
8.
Shao S, Chan Y, Lin S, Li C, Kao Yang Y, Chen Y, et al.
PLoS One
. 2020 Apr;
15(4):e0231482.
PMID: 32315319
Objective: To evaluate the influence of pharmacists' dispensing workload (PDW) on pharmacy services as measured by prescription suggestion rate (PSR) and dispensing error rate (DER). Method: This was an observational...
9.
Shao S, Chang K, Lin S, Chien R, Hung M, Chan Y, et al.
Cardiovasc Diabetol
. 2020 Feb;
19(1):17.
PMID: 32050968
Background: Sodium glucose cotransporter 2 (SGLT2) inhibitors have shown greater reductions of cardiovascular event risks than dipeptidyl peptidase-4 (DPP4) inhibitors, whereby possible mechanisms may involve the better pleiotropic effects of...
10.
Shao S, Lin Y, Chang K, Chan Y, Hung M, Kao Yang Y, et al.
BMJ Open Diabetes Res Care
. 2020 Feb;
7(1).
PMID: 32043472
Objective: This study evaluated the characteristics of new users of sodium glucose co-transporter 2 inhibitors (SGLT2i) in clinical practice to assess the applicability of the findings from clinical trials (Empagliflozin,...